By Daniella Parra
Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, said its net loss was $5.4 million for the three months ended March 31, compared to $6.2 million in 2023.
The company said an experimental drug to improve the delivery of anti-cancer medications to solid tumors has shown promise in preclinical models and clinical trials, including safety and tolerability in pancreatic cancer patients.
The company said it has sufficient funds to support operations into early 2026.
“These results will be instrumental in determining the future of Lisata, and we plan to use them to explore conditional approvals with various regulatory agencies and/or to design an optimized Phase 3 program in pancreatic ductal adenocarcinoma,” said David J. Mazzo, Ph.D., President and Chief Executive Officer.
Contact:
